How is KISQALI dosed in metastatic breast cancer?
For patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC), the starting dose for KISQALI® (ribociclib) is 600 mg (3 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off), in combination with an aromatase inhibitor (AI) or fulvestrant. Learn about KISQALI dosing for mBC below.1
DOSING
For your patients with HR+/HER2- mBC,
Start with KISQALI 600 mg—the once-daily starting dose with proven outcomes
(28-day cycle)1 | Week 1 | Week 2 | Week 3 | Week 4 | Subsequent cycles |
KISQALI: 3 tablets |  | | |  |  Repeat |
AI |  | | | | |
or | |||||
KISQALI: 3 tablets | | | | | Repeat |
Fulvestrant | Day 1 injection |  | Day 15 injection | | Once monthly |
KISQALI is given as 600 mg (3 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off) with either AI or fulvestrant1:
AI should be taken once daily (continuously); in men and premenopausal women, an LHRH agonist should be administered according to current clinical practice guidelines; or
Fulvestrant 500 mg should be administered intramuscularly on Days 1, 15, and 29, and once monthly thereafter; in men and premenopausal women, an LHRH agonist should also be administered according to current clinical practice guidelines
Patients should continue treatment until disease progression or unacceptable toxicity
Please refer to the full Prescribing Information for fulvestrant
Please refer to the full Prescribing Information for the recommended dose of the chosen AI
KISQALI can be taken with or without food
Patients may store at room temperature at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)
Store in the original blister package in order to protect from moisture
Starting dose modifications for hepatic and severe renal impairment1
The recommended starting dose is 400 mg once daily for patients with moderate or severe (Child-Pugh class B or C) hepatic impairment
The recommended starting dose is 200 mg once daily for patients with severe renal impairment
AI, aromatase inhibitor; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinizing hormone-releasing hormone; mBC, metastatic breast cancer.
PEER PERSPECTIVE
Nick McAndrew, MD, discusses KISQALI dose adjustments and patient adherence in HR+/HER2- mBC
How do KISQALI single-strength tablets allow for simple dose reductions? Dr McAndrew shares his perspective and personal insights from his experience with KISQALI dose adjustments in HR+/HER2- mBC.
Dr McAndrew has been compensated for his time by Novartis Pharmaceuticals Corporation.
